Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesDMD Digital Health Connections Group Inc

DMD Digital Health Connections Group Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-11T21:11:59.880218Z
Market Cap
4.42M

Momentum Score

…

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.64
Low
2.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on DMD Digital Health Connections Group Inc (ticker APTOF) is limited, so its precise business activities and financial profile are not clearly documented. Potential long-term growth drivers would be linked to adoption of digital health services and data-driven care models, and investors may find the company attractive if it establishes scalable offerings, sustainable revenue and transparent reporting.

The principal investment risk is the lack of transparent public filings and operating disclosure, which creates material execution, liquidity and financing uncertainty that investors should monitor.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
26.94M
ROCE
-3501.84%
Diluted EPS TTM
-10.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -25.47M -25.43M -51.21M -41.82M -65.35M
Net income -25.47M -25.43M -51.21M -41.82M -65.35M
Selling general administrative 13.36M 11.13M 15.54M 14.43M 19.32M
Reconciled depreciation 0.42M 0.40M 0.47M 0.53M 0.62M
Operating income -24.72M -26.26M -52.36M -42.60M -65.45M
Interest expense 0.84M 0.21M 0.00M - -
Interest income 0.10M 0.36M 1.15M 0.79M 0.09M
Net interest income -0.74M 0.15M 1.15M 0.79M 0.09M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 24.72M 26.26M 52.36M 42.60M 65.45M
Total other income expense net -0.01M 0.68M -0.00M -0.01M -0.00M
Net income from continuing ops -25.47M -25.43M -51.21M -41.82M -65.35M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.01M 10.13M 12.99M 51.03M 82.53M
Other current assets 0.14M 0.57M 0.60M 0.26M 0.13M
Total liab 37.18M 14.67M 15.89M 13.29M 8.29M
Total stockholder equity -27.17M -4.54M -2.90M 37.74M 74.24M
Capital stock 459.77M 457.40M 444.81M 437.52M 437.39M
Retained earnings -566.43M -540.97M -515.54M -464.33M -422.51M
Cash 0.94M 6.15M 9.25M 36.97M 39.11M
Total current liabilities 9.31M 4.46M 15.27M 12.28M 8.17M
Net debt 26.94M 3.87M - - -
Total current assets 6.45M 9.53M 11.89M 49.52M 81.74M
Short term investments - - 0.00M 9.99M 40.01M
Long term debt 27.87M 10.02M - - -
Accounts payable 2.91M 1.26M 3.49M 3.34M 1.70M
Non currrent assets other 3.39M - - - -
Non current assets total 3.57M 0.60M 1.09M 1.51M 0.79M
Capital lease obligations 0.19M 0.62M 1.01M 1.30M 0.57M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 9.99M 30.09M -35.00M
Net borrowings 18.55M 10.00M 0.00M - -
Total cash from financing activities 19.38M 33.41M 6.91M 0.12M 0.23M
Net income -25.47M -25.43M -51.21M -41.82M -65.35M
Change in cash -2.61M -2.54M -27.72M -2.14M -78.28M
Begin period cash flow 6.71M 9.25M 36.97M 39.11M 117.39M
End period cash flow 4.10M 6.71M 9.25M 36.97M 39.11M
Total cash from operating activities -21.99M -35.98M -44.59M -32.32M -43.30M
Issuance of capital stock 0.83M 23.41M 6.88M 0.10M 0.04M
Depreciation 0.42M 0.40M 0.47M 0.53M 0.62M
Sale purchase of stock 0.00M -0.02M - - -
Capital expenditures 0.00M 0.01M 0.03M 0.02M 0.21M
Change in working capital 2.17M -11.03M 2.81M 4.32M 1.52M
Stock based compensation 0.48M 1.06M 3.65M 5.21M 12.95M
Other non cash items 0.41M -0.38M -0.31M -0.57M 6.97M
Free cash flow -21.99M -35.98M -44.62M -32.35M -43.52M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

DMD Digital Health Connections Group Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

66 Wellington Street West, Toronto, ON, Canada, M5K 1E6

647 479 9828

https://www.aptose.com

14

Name Title Year Born
Dr. William G. Rice Ph.D. Chairman, President & CEO 1959
Mr. Fletcher Payne Senior VP, CFO, Chief Business Officer & Secretary 1963
Dr. Rafael Bejar M.D., Ph.D. Senior VP & Chief Medical Officer 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…